IMiDs

IMiDs®: IMiDs compounds are proprietary novel small molecule, orally available compounds that modulate the immune system and other biologically important targets through multiple mechanisms of action. We have advanced four IMiDs compounds into development: REVLIMID® (lenalidomide), CC-4047 (pomalidomide) and CC-11006 are being evaluated in human clinical trials, and CC-10015 is advancing toward potential clinical testing.

Other IMiDs compounds with more selective activity are also being evaluated.

Our IMiDs compounds are covered by an extensive and comprehensive intellectual property estate of U.S. and foreign-issued patents and pending patent applications, including composition-of-matter, use and other patents and patent applications.

REVLIMID®: REVLIMID® is the first of the IMiDs compounds to gain FDA approval. REVLIMID® is an oral immunomodulatory drug that is FDA approved for the treatment of certain patients with myelodysplastic syndromes. The FDA and EMEA subsequently approved REVLIMID® for use in multiple myeloma.

Celgene continues to pursue a broad clinical development program for REVLIMID®. Currently, there are a substantial number of advanced stage clinical trials evaluating the potential of REVLIMID® across a broad range of cancer-related and other debilitating diseases.

In addition to our pivotal REVLIMID® trials, a number of cooperative research groups have initiated trials with REVLIMID®. More information on these and other REVLIMID® trials can be found on the website: www.clinicaltrials.gov.

CC-4047: One of the most potent IMiDs compounds in our portfolio with a multi-factorial mechanism of action, including:

Plans are in place to advance this compound into Phase II trials to further evaluate its efficacy and safety profile in several hematologic malignancies and solid tumors.

CC-11006: A molecule we have identified as a potential treatment for hematological malignances, neurodegenerative disorders, and chronic inflammatory diseases, many of which have unmet medical needs. CC-11006 appears to be non-bone marrow suppressive while retaining the ability to modulate levels of key pro-inflammatory and regulatory cytokines. CC-11006 is now in early stage trials to evaluate its profile in myelodysplastic disorders.

CC-4047 and CC-11006 are not approved by the FDA in any indication and are currently being evaluated in clinical trials for efficacy and safety for future regulatory applications.

The products represented as in development and found in the product pipeline are intended for investors and members of the media to provide general information on Celgene. This information is not represented to be a complete description and is subject to change without notice. Celgene Corporation may from time to time update this information but does not warrant that will take place at any particular time nor assume any obligation to update this information.